|Day Low/High||53.76 / 55.27|
|52 Wk Low/High||36.15 / 57.44|
AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.
Here is a round-up of the headlines from Europe.
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.
For the week of November 7, all eyes will be on Tuesday's presidential election.
Stocks in the health care sector seem to have no underpinnings whatsoever.
Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.
Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.
Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
Pfizer is making another acquisition.
Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session.
Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.
Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.
I am starting to get more confident that the small caps are ready to bounce.
AZN looks vulnerable to further declines. The next downside support area and price target are the $26-$24 area.
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.